Accessibility Menu
Tevogen Bio logo

Tevogen Bio(NASDAQ) TVGN

Market Cap$45.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-99%
5 YearN/A
1 Year-86%
1 Month+22%
$6.79
-3.69%
-0.26Today
Tevogen Bio last closing stock price
MetricPriceDate
Last closeUSD 7.022026-08-03
Tevogen Bio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+26.03%USD 5.572026-07-27
1 month+21.66%USD 5.772026-07-02
3 month-4.75%USD 7.372026-05-05
Year to date-57.6%USD 16.562025-12-31
1 year-85.96%USD 50.002025-08-01
3 year-98.69%USD 536.002023-08-04
Since inception-98.59%USD 496.842022-01-05

Tevogen Bio Financials at a Glance

Market Cap

$45.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$21.35M

EPS (TTM)

-$5.84

P/E Ratio

-1.20

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$6.79

Volume

68

Open

$7.23

Previous Close

$7.02

Daily Range

$6.43 - $7.36

52-Week Range

$3.64 - $70.00

Estimated Earnings Date

Aug 13, 2026

TVGN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Tevogen Bio

Tevogen develops cell-based therapies for serious diseases like COVID-19 and cancer. Its products aim to help patients with limited treatment options. The company focuses on making these therapies available quickly and efficiently.

Lab Coats and Life Savers: Products and Services

  • Precision T cell therapies: Off-the-shelf treatments using immune cells to target viruses and cancers; 0% of revenue (no sales yet).
  • TVGN 489: Lead product for high-risk COVID-19 and long COVID patients; 0% of revenue.
  • TVGN 920/960: Products in development for cancers linked to human papillomavirus (HPV); 0% of revenue.
  • TVGN 116/601/930: Pipeline therapies for hepatitis B, multiple sclerosis, and certain lymphomas; 0% of revenue.
  • Tevogen.AI: Early-stage artificial intelligence project to speed up drug development; 0% of revenue.

Growth Spurts and Science Sprints: Growth and Expansion

  • Completed Phase 1 trial for TVGN 489 in high-risk COVID-19 patients in 2023.
  • Expanded ExacTcell platform to new disease areas in 2024 and 2025.
  • Leased expanded headquarters in Warren, NJ in 2025; Philadelphia R&D facility lease expired in 2025.
  • Signed letter of intent in 2026 to acquire over 50% of a clinical research organization.
  • Formed collaborations with AI and technology companies in 2025 to support drug development.

Why Tevogen Is a Bit Different

Tevogen uses a process called ExacTcell to create cell therapies from healthy donors, aiming for quick and scalable production. Its therapies are designed to work for many patients without genetic modification. The company integrates artificial intelligence to improve research and development speed.

Five Things You Need to Know

  • No revenue reported in 2023, 2024, or 2025.
  • Net loss was $26.3 million in 2025, compared to $13.7 million in 2024.
  • Cash was $0.6 million at December 31, 2025, with $12.6 million in liabilities.
  • Operating expenses were $26.1 million in 2025, compared to $53.6 million in 2024.
  • Company relies on external funding and has not yet launched commercial products.

Bottom Line

Tevogen is an early-stage biotech focused on cell therapies for hard-to-treat diseases. The company is investing in research and infrastructure but has yet to generate revenue.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

18

CEO

Ryan Saadi, MD

Website

www.tevogen.com

Headquarters

Warren, NJ 07059, US

TVGN Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

241.39%

Return on Capital

N/A

Return on Assets

-433.95%

Earnings Yield

-83.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$45.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

6.42M

Volume

68

Avg. Volume

27.11K

Financials (TTM)

Gross Profit

-$144.84K

Operating Income

-$21.19M

EBITDA

-$20.83M

Operating Cash Flow

-$11.75M

Capital Expenditure

-$64.43K

Free Cash Flow

-$11.82M

Cash & ST Invst.

$692.31K

Total Debt

$3.07M

Tevogen Bio Performance Analysis

Tevogen Bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Tevogen Bio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Tevogen Bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 4.60N/A
20232023-12-31USD -122.17N/A
20242024-12-31USD -3.50-97.1%
20252025-12-31USD -8.08130.7%
Tevogen Bio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3053.0%
Q32025-09-302.0%
Q42025-12-3120.0%
Q12026-03-31-34.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$59.05K

N/A

Gross Margin

0.00%

N/A

Market Cap

$45.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.50M

N/A

Employees

18

N/A

Net Income

-$5.45M

+47.5%

EBITDA

-$5.46M

+46.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$692.31K

-64.9%

Total Debt

$3.07M

-36.3%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$1.09M

-63.5%

Short Term Debt

$1.98M

+8.6%

Return on Assets

-4.34%

N/A

Return on Invested Capital

9.02%

N/A

Free Cash Flow

-$2.73M

+17.4%

Operating Cash Flow

-$2.73M

+17.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TILInstil Bio, Inc.
$7.22+1.40%
CLNNClene Inc.
$5.19+3.49%
ATOSAtossa Therapeutics, Inc.
$2.17+4.83%
ONCYOncolytics Biotech Inc.
$0.78+2.88%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.36+0.02%
PLTRPalantir Technologies
$125.65+0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$41.43-0.05%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$23.99+0.01%

Questions About TVGN

What is the current price of Tevogen Bio?

Tevogen Bio is trading at $7.02 per share.

What is the 52-week range for Tevogen Bio?

Over the past 52 weeks, Tevogen Bio has traded between $3.64 and $70.00.

How much debt does Tevogen Bio have?

As of the most recent reporting period, Tevogen Bio reported total debt of $9.47M.

How much cash does Tevogen Bio have on hand?

Tevogen Bio reported $692.31K in cash and cash equivalents in its most recent financial results.

What is Tevogen Bio’s dividend yield?

Tevogen Bio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services